Buscar resultados de ensayos clínicos
Mantle Cell Lymphoma - 26 Studies Found
| Estado | Estudiar |
| Completed |
Nombre del estudio: Combination of Bortezomib, Fludarabine and Cyclophosphamide Treat Recurrent Mantle Cell Lymphoma Condición: Mantle Cell Lymphoma Recurrent Fecha: 2011-03-24 Intervenciones: Drug: Combination of Bortezomib, Fludarabine and Cyclophosphamide bortezomib 1.3mg/m^2 i.v. on days 1, 4 |
| Withdrawn |
Nombre del estudio: A Study of Acalabrutinib in Combination With Rituximab Versus Ibrutinib Versus Acalabrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma Condición: Mantle Cell Lymphoma Fecha: 2016-04-08 Intervenciones:
|
| Active, not recruiting |
Nombre del estudio: A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma Condición: Mantle Cell Lymphoma Fecha: 2013-01-24 Intervenciones:
|
| Completed |
Nombre del estudio: Combination of Ibrutinib and Bortezomib to Treat Patients With Mantle Cell Lymphoma Condición: Mantle Cell Lymphoma Fecha: 2015-02-02 Intervenciones:
|
| NOT_YET_RECRUITING |
Nombre del estudio: Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma Condición: Fecha: 2025-08-02 Intervenciones: Undergo biopsy |
| Completed |
Nombre del estudio: Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma Condición: Mantle Cell Lymphoma Fecha: 2025-08-02 Intervenciones: Given PO |
| Completed |
Nombre del estudio: Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma Condición: Blastoid Variant Mantle Cell Lymphoma Fecha: 2025-08-02 Intervenciones: Undergo tumor biopsy |
| NOT_YET_RECRUITING |
Nombre del estudio: A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Na�ve Mantle Cell Lymphoma Condición: Mantle Cell Lymphoma (MCL) Fecha: 2025-08-02 Intervenciones: Investigational Product |
| Completed |
Nombre del estudio: A Study of Tafasitamab and Lenalidomide in People With Mantle Cell Lymphoma Condición: Mantle Cell Lymphoma Fecha: 2025-08-02 Intervenciones: Participants will receive treatment with intravenous tafasitamab and oral lenalidomide for up to 12 cycles.Each cycle is 28 days in length. |
| NOT_YET_RECRUITING |
Nombre del estudio: Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma Condición: Mantle Cell Lymphoma Fecha: 2025-08-02 Intervenciones: Given PO |